NCT03189589 - Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2017

Primary Completion Date

July 24, 2017

Study Completion Date

July 24, 2017

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK2269557 500 µg

GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.

DRUG

GSK2269557 750 µg

GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.

Trial Locations (1)

CB2 0GG

GSK Investigational Site, Cambridge